News|Articles|July 3, 2025

Lupin receives FDA approval for Loteprednol Etabonate Ophthalmic Gel, 0.38%

Author(s)Kassi Filkins

Lupin Limited secures FDA approval for Loteprednol Etabonate Ophthalmic Gel, enhancing treatment options for postoperative ocular inflammation and pain.

Lupin Limited recently announced the US Food and Drug Administration (FDA) approval for the company’s Abbreviated New Drug Application for Loteprednol Etabonate Ophthalmic Gel, 0.38%.1

Loteprednol Etabonate Ophthalmic Gel, 0.38% is a corticosteroid for the treatment of postoperative inflammation and pain following ocular surgery. It is the bioequivalent to Bausch & Lomb’s Lotemax SM Ophthalmic Gel. Additionally, Loteprednol Etabonate Ophthalmic Gel, 0.38% had an estimated annual sale of $29 million in the US, according to a press release.

Lupin is eligible for 180 days of drug exclusivity, as the company is the exclusive first-to-file for the product.

Reference:
  1. kw2023. Lupin and Sino Universal Pharmaceuticals Sign License and Supply Agreement for Tiotropium DPI in China. Lupin. Published July 2025. Accessed July 1, 2025. https://www.lupin.com/lupin-receives-approval-from-u-s-fda-for-loteprednol-etabonate-ophthalmic-gel/

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Latest CME